Bristol-Myers Squibb Co. vs. Johnson & Johnson
Bristol-Myers Squibb Co. (BMY) comes out ahead, leading on 7 of 11 compared factors.
Size & Scale
| BMY | JNJ | |
|---|---|---|
| Market Cap | $129.92 billion | $651.20 billion |
| Revenue (TTM) | $49.19 billion | $97.93 billion |
| Net Income (TTM) | $9.27 billion | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| BMY | JNJ | |
|---|---|---|
| P/E Ratio | 13.84 | 31.51 |
| Price / Book | 5.82 | 7.66 |
| Price / Sales | 2.64 | 6.65 |
BMY leads on 3 of 3 valuation factors.
Profitability
| BMY | JNJ | |
|---|---|---|
| Net Margin | 18.85% | 21.48% |
| Return on Equity | 41.55% | 24.76% |
BMY and JNJ split the profitability factors evenly.
Dividend
| BMY | JNJ | |
|---|---|---|
| Dividend Yield | 4.01% | 1.97% |
| Payout Ratio | 55.51 | 62.18 |
BMY leads on 2 of 2 dividend factors.
Risk & Sentiment
| BMY | JNJ | |
|---|---|---|
| Short Interest | 0.39% | 0.67% |
BMY leads on 1 of 1 risk & sentiment factors.
Dig deeper: BMY overview, BMY financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
